135 related articles for article (PubMed ID: 22673737)
1. Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin.
Hung SH; Lee FP; Su CH; Tseng H
Eur Arch Otorhinolaryngol; 2013 Feb; 270(2):695-704. PubMed ID: 22673737
[TBL] [Abstract][Full Text] [Related]
2. SPLUNC1 is associated with nasopharyngeal carcinoma prognosis and plays an important role in all-trans-retinoic acid-induced growth inhibition and differentiation in nasopharyngeal cancer cells.
Zhang W; Zeng Z; Wei F; Chen P; Schmitt DC; Fan S; Guo X; Liang F; Shi L; Liu Z; Zhang Z; Xiang B; Zhou M; Huang D; Tang K; Li X; Xiong W; Tan M; Li G; Li X
FEBS J; 2014 Nov; 281(21):4815-29. PubMed ID: 25161098
[TBL] [Abstract][Full Text] [Related]
3. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
[TBL] [Abstract][Full Text] [Related]
4. Combinations of indole based alkaloids from Mitragyna speciosa (Kratom) and cisplatin inhibit cell proliferation and migration of nasopharyngeal carcinoma cell lines.
Domnic G; Jeng-Yeou Chear N; Abdul Rahman SF; Ramanathan S; Lo KW; Singh D; Mohana-Kumaran N
J Ethnopharmacol; 2021 Oct; 279():114391. PubMed ID: 34224811
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.
Hsu CH; Gao M; Chen CL; Yeh PY; Cheng AL
Oncology; 2005; 68(4-6):538-47. PubMed ID: 16037687
[TBL] [Abstract][Full Text] [Related]
6. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
[TBL] [Abstract][Full Text] [Related]
7. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of autophagy inhibitors combined with cisplatin against cisplatin-resistant nasopharyngeal cancer cells.
Yin W; Xu J; Mao Y
Biochem Cell Biol; 2021 Jun; 99(3):322-329. PubMed ID: 34038188
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin.
Liu RY; Peng JL; Li YQ; Huang BJ; Lin HX; Zhou L; Luo HL; Huang W
Anat Rec (Hoboken); 2013 Dec; 296(12):1833-41. PubMed ID: 24136729
[TBL] [Abstract][Full Text] [Related]
10. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid phenethyl ester suppressed growth and metastasis of nasopharyngeal carcinoma cells by inactivating the NF-κB pathway.
Liang Y; Feng G; Wu L; Zhong S; Gao X; Tong Y; Cui W; Qin Y; Xu W; Xiao X; Zhang Z; Huang G; Zhou X
Drug Des Devel Ther; 2019; 13():1335-1345. PubMed ID: 31118570
[No Abstract] [Full Text] [Related]
12. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma.
Cao JY; Liu L; Chen SP; Zhang X; Mi YJ; Liu ZG; Li MZ; Zhang H; Qian CN; Shao JY; Fu LW; Xia YF; Zeng MS
Mol Cancer; 2010 Sep; 9():237. PubMed ID: 20828406
[TBL] [Abstract][Full Text] [Related]
15. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
16. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
18. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.
Voon YL; Ahmad M; Wong PF; Husaini R; Ng WT; Leong CO; Lane DP; Khoo AS
Oncol Rep; 2015 Oct; 34(4):1692-700. PubMed ID: 26252575
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
[TBL] [Abstract][Full Text] [Related]
20. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
Caliaro MJ; Vitaux P; Lafon C; Lochon I; Néhmé A; Valette A; Canal P; Bugat R; Jozan S
Br J Cancer; 1997; 75(3):333-40. PubMed ID: 9020476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
